Physician profile
Autumn E Warnock
NPI 1174945372
$2,857.14
in general payments reported to CMS, 2019-2025
22 companies · $607 in 2025
The $607 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $416 · 2022: $449 · 2023: $810 · 2024: $576 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,858 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,858.01 |
| Education | $134.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $742.39 | 2021-2024 | |
| Astellas Pharma US INC | $400.08 | 2023-2025 | Veozah |
| Pfizer INC. | $256.86 | 2021-2024 | |
| Myriad Women'S Health, INC. | $213.13 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $194.44 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $182.27 | 2023-2025 | |
| Novo Nordisk INC | $136.06 | 2021-2025 | Wegovy |
| Abiomed | $119.83 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $117.69 | 2021-2025 | |
| Sage Therapeutics, LLC | $90.13 | 2024-2025 | Zurzuvae |
| Myovant Sciences INC. | $87.41 | 2021-2022 | |
| Hologic Sales and Service, LLC | $62.69 | 2021-2025 | Acessa Provu System, Omni Hysteroscope, Novasure |
| Exeltis, USA INC. | $45.13 | 2022-2025 | Slynd |
| Therapeuticsmd, INC. | $44.17 | 2022 | |
| Exact Sciences Corporation | $38.91 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Virtus Pharmaceuticals LLC | $31.51 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $19.93 | 2025 | Gardasil 9 |
| Organon LLC | $16.00 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $14.82 | 2025 | Qelbree |
| Avion Pharmaceuticals | $14.81 | 2023 | Balcoltra |
| Convatec INC. | $14.64 | 2021 | |
| Biogen, INC. | $14.24 | 2024 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Autumn Warnock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.